Thyrogen gains thyroid cancer ablation indication
The FDA has approved the use of Thyrogen (thyrotropin alfa for injection) to be used in combination with radioiodine to ablate or destroy any remaining thyroid tissue in patients who have had cancerous thyroids removed. Remnant ablation is a common procedure for patients undergoing thyroid cancer treatment. Thyrogen is already indicated for use as an adjunctive diagnostic tool for serum thyroglobulin testing with or without radioiodine imaging of patients with well-differentiated thyroid cancer.
For more information call (888) 497-6436 or visit www.thyrogen.com.